Pharmaceutical Economics and LDL-C Management
Implications for PCSK9 Inhibitors in Clinical Practice
Clinician Resource
PCSK9 Inhibitor Clinic Model
Educational materials for clinicians.
Patient Resources
Centers for Disease Control and Prevention
Educational materials for patients with high cholesterol.
American Heart Association
Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.
The FH Foundation
A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).
Clinical Assessment Tools
ASCVD Risk Estimator
Dutch Lipid Clinic Network Score for Familial Hypercholesterolemia
Guidelines
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, et al. Circulation. 2019;139(25):e1046-e1081.
Suggested Readings
PCSK9 inhibitor valuation: a science-based review of the two recent models.
Baum SJ, Cannon CP. Clin Cardiol. 2018;41(4):544-550.
Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease.
Fonarow GC, et al. JAMA Cardiol. 2017;2(10):1069-1078.
Evolocumab for treatment of high cholesterol: effectiveness and value.
Institute for Clinical and Economic Review. 2017.
Alirocumab for treatment of high cholesterol: effectiveness and value.
Institute for Clinical and Economic Review. 2019.
Application of PCSK9 inhibitors in practice: challenges and opportunities.
Kaufman TM, et al. Circ Res. 2017;121(5):499-501.
Application of PCSK9 inhibitors in practice: the patient experience.
Kaufman TM, et al. Circ Res. 2019;124(1):32-37.
Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY Outcomes trial.
Kazi DS, et al. Ann Intern Med. 2019;170(4):221-229.
Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial.
Murphy SA, et al. JAMA Cardiol. 2019;4(7):613-619.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial.
Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.
Alirocumab and cardiovascular outcomes after acute coronary syndrome.
Schwartz GG, et al. N Engl J Med. 2018;379(22):2097-2107.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.
Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial.
Szarek M, et al. J Am Coll Cardiol. 2019;73(4):387-396.
Interactive PresentationDr Sergio Fazio discusses his PCSK9 inhibitor clinic model
Implications for PCSK9 Inhibitors in Clinical Practice
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management
